Tweet
Altfest L J & Co. Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 67.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,908 shares of the biopharmaceutical company's stock after selling 8,015 shares during the quarter. Altfest L J & Co. Inc.'s holdings in Gilead Sciences were worth $277,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Dynamic Advisor Solutions LLC grew its holdings in shares of Gilead Sciences by 58.2% during the second quarter. Dynamic Advisor Solutions LLC now owns 4,979 shares of the biopharmaceutical company's stock worth $354,000 after buying an additional 1,831 shares during the last quarter. FTB Advisors Inc. lifted its position in Gilead Sciences by 1.3% in the second quarter. FTB Advisors Inc. now owns 73,220 shares of the biopharmaceutical company's stock valued at $5,186,000 after purchasing an additional 973 shares during the period. Strs Ohio lifted its position in Gilead Sciences by 1.2% in the second quarter. Strs Ohio now owns 932,992 shares of the biopharmaceutical company's stock valued at $66,093,000 after purchasing an additional 10,668 shares during the period. Toronto Dominion Bank lifted its position in Gilead Sciences by 21.7% in the second quarter. Toronto Dominion Bank now owns 1,140,476 shares of the biopharmaceutical company's stock valued at $82,608,000 after purchasing an additional 203,518 shares during the period. Finally, Lipe & Dalton lifted its position in Gilead Sciences by 21.7% in the second quarter. Lipe & Dalton now owns 61,526 shares of the biopharmaceutical company's stock valued at $4,359,000 after purchasing an additional 10,966 shares during the period. 77.70% of the stock is currently owned by institutional investors. Get Gilead Sciences alerts:
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $70.81, for a total transaction of $3,540,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $217,228,227.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . Over the last quarter, insiders have sold 150,000 shares of company stock valued at $10,839,500. Insiders own 1.16% of the company's stock. GILD stock opened at $75.59 on Friday. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.23, a current ratio of 3.00 and a quick ratio of 2.92. The company has a market cap of $99.47 billion, a PE ratio of 8.83, a P/E/G ratio of -5.85 and a beta of 1.03.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The company had revenue of $5.65 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same period last year, the firm earned $2.56 EPS. The company's revenue for the quarter was down 20.9% on a year-over-year basis. analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.02%. Gilead Sciences's payout ratio is 26.64%.
GILD has been the subject of a number of recent analyst reports. Piper Jaffray Companies initiated coverage on shares of Gilead Sciences in a research report on Wednesday, May 30th. They issued a "buy" rating and a $85.00 price objective for the company. Barclays reduced their price objective on shares of Gilead Sciences from $95.00 to $90.00 and set a "buy" rating for the company in a research report on Wednesday, May 2nd. ValuEngine downgraded shares of Gilead Sciences from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Gilead Sciences from a "sell" rating to a "buy" rating and set a $85.00 price objective for the company in a research report on Thursday, April 19th. Finally, Mizuho set a $94.00 price objective on shares of Gilead Sciences and gave the company a "buy" rating in a research report on Tuesday, July 31st. Twelve investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences currently has an average rating of "Buy" and an average price target of $88.00.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases